Cancer Biopsy Market to Command US$ 131.4 Billion Backed by Soaring 18% CAGR Growth By the end of 2033

According to a recently published Future Market Insights report, the Cancer Biopsy Market revenues were estimated at US$ 22.2 Bn in 2022 and are anticipated to grow at a CAGR of 18% from 2023-2033. By the end of 2033, the market is expected to reach US$ 131.4 Bn.

The increasing elderly populace, along with the rise in cancer diagnoses, is fueling growth in the cancer clinical market. Also, the practical and less costly use of liquid biopsy procedures and increasing biopsy appointees are all expected to impact the market growth.

Some of today's prominent procedures in medical diagnosis include endoscopic, arthroscopic, bone marrow, skin, needle, and surgical biopsies. Needle biopsies are regarded as a trusted method for the early detection of patients suffering from these methods. However, fine-needle aspiration needle biopsies, which are less invasive and faster, are aiding the increase in popularity of the slice.

Unlock the Treasures of Knowledge with our PDF Samples.@
https://www.futuremarketinsights.com/reports/sample/rep-gb-16508

The IARC estimates that by 2020 the worldwide burden of disease due to cancer is projected to be 19.3 million cases and 9.96 million deaths worldwide. A liquid biopsy entails reduced expense, earlier prognosis, therapy surveillance, identification of tumor heterogeneity, acquired drug resistance, and patient comfort compared to conventional diagnostic tools for handling cancer.

Competitive Analysis

Key companies are helping to drive market expansion by diversifying their diagnostics portfolios and increasing the adoption of their biopsy tools.

Key recent developments of key players in the Cancer Biopsy Market are as follows:

-In March 2021, in Russia, KIllumina, Inc. received medical device approval for their NextSeq 550Dx platform and related reagent kits. Before this registration, the MiSeq Dx had already been approved as a medical device.
-In March 2021, Autopsy with Quick-Core IZI Medical Products introduced a system for soft tissue biopsy procedures. This fully automated product is based on Quick-Core, the company's patented semi-automatic method.

Competitive Landscape

Key companies are helping to drive market expansion by diversifying their diagnostics portfolios and increasing the adoption of their biopsy tools.

-In March 2021, In Russia, KIllumina, Inc. received medical device approval for their NextSeq 550Dx platform and related reagent kits. Before this registration, the MiSeq Dx had already been approved as a medical device.
-In March 2021, Autopsy with Quick-Core IZI Medical Products introduced a system for soft tissue biopsy procedures. This fully automated product is based on Quick-Core, the company's patented semi-automatic method.
-In April 2021, Plasma-SeqSensei liquid biopsy research use-only (RUO) kits were introduced in EMEA by Sysmex Europe GmbH and Sysmex Inostics GmbH.

Witness the transformation brought by our methodology insights today. @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16508

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Cancer Biopsy Market, presenting historical market data (2018-2022) and forecast statistics for the period of 2023-2033.

The study reveals essential insights based on Type (Tissue Biopsies, Liquid biopsies, Other Types), Product Type (Instruments, Kits, Consumables, Services), Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Liver Cancers, Pancreatic Cancers, Ovarian Cancers, Other Applications) across five regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

Market Segments Covered in Cancer Biopsy Industry Analysis

By Type:

-Tissue Biopsies
--Needle Biopsies
--Surgical Biopsies
-Liquid Biopsies
-Other Types

By Product Type:

-Instruments
-Kits and Consumables
-Services

By Application:

-Breast Cancer
-Colorectal Cancer
-Cervical Cancers
-Lung Cancers
-Prostate Cancers
-Skin Cancers
-Blood Cancers
-Kidney Cancers
-Liver Cancers
-Pancreatic Cancers
-Ovarian Cancers
-Other Applications

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Access Full Report, Act Informed: @
https://www.futuremarketinsights.com/reports/cancer-biopsy-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization, and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel, and End Use over the next 10 years.

This release was published on openPR.